Valuation: Depomed Inc

Market Cap 152M 133M 123M 113M 215M 14.48B 219M 1.47B 575M 7.13B 570M 558M 24.55B P/E 2027 *
-
P/E 2028 * -
Enterprise Value 129M 113M 104M 96.07M 182M 12.27B 185M 1.24B 487M 6.05B 483M 473M 20.81B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
98.57%
Yield 2027 *
-
Yield 2028 * -
Director TitleAgeSince
Director/Board Member - 2026-06-15
Director/Board Member 26 2026-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-9.45%+3.54% - - 152M
-2.33%-2.09%+50.33%+162.29% 1,085B
-0.82%-2.30%+62.97%+61.11% 624B
-0.73%-4.98%+27.22%+84.46% 442B
+0.33%-1.17%+27.98%+26.90% 332B
-0.02%-2.85%+25.27%+44.88% 282B
-3.89%-11.72%+23.86%+26.94% 277B
+0.66%-2.94%-27.27%-39.99% 217B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 167B
Average -1.65%-1.86%+24.97%+55.54% 402.44B
Weighted average by Cap. -0.45%-1.06%+35.72%+81.72%

Financials

2027 *2028 *
Net sales - -
Net income 400K 350K 323K 299K 566K 38.15M 576K 3.86M 1.51M 18.79M 1.5M 1.47M 64.67M -
Net Debt - -
Logo Depomed Inc
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Employees
-